June 24, 2019 11:00 UTC Additional Data Points to Potential of XERAVA to Treat Carbapenem-Resistant, Multidrug-Resistant Escherichia Coli TP-6076 Demonstrates In Vivo Efficacy in Murine Lung and Thigh Infection Models with Acinetobacter Baumannii WATERTOWN,...
Ongoing pivotal Phase II clinical trial of ADCT-402 in patients with relapsed or refractory diffuse large B-cell lymphoma anticipated to complete enrollment in third quarter of 2019 Pivotal Phase II clinical trial of ADCT-301 in relapsed or refractory Hodgkin lymphoma...
Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metrics important to PBC patients, including fatigue...
Mallinckrodt plc(NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company’s Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin...
Primary endpoint, defined as Latency to Persistent Sleep (LPS) at Night 1, showed improvement with a p-value ≤0.001 after treatment with 10 and 20 mg doses of seltorexant Key secondary endpoint, defined as Wake After Sleep Onset over first 6 hours (WASO‑6) at Night 1,...
Email
Text